Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03907826

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma Clinical Trial

Official title:
PD-1 Antibody Combined With Chemoradiotheapy vs. Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients: a Multicenter, Randomised Controlled, Phase III Clinical Trial

Clinical Trial Summary

This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03907826
Study type Interventional
Source Sun Yat-sen University
Contact Jingjing Miao
Phone 02087342638
Email miaojingjing90@163.com
Status Recruiting
Phase Phase 3
Start date March 1, 2020
Completion date December 2027
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06010095 - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Phase 2
Recruiting NCT03639467 - Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma Phase 1/Phase 2
Recruiting NCT06029270 - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase 2
Recruiting NCT03666221 - Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05350891 - Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC Phase 2
Active, not recruiting NCT04586088 - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Phase 2
Active, not recruiting NCT04405622 - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 2
Recruiting NCT06235203 - Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC Phase 3
Not yet recruiting NCT04215510 - Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT Phase 3
Recruiting NCT03930498 - Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT04376866 - Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT05432219 - A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma N/A
Recruiting NCT04425265 - Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma N/A
Not yet recruiting NCT03689556 - Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
Not yet recruiting NCT03210389 - A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. Phase 2
Completed NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Phase 2
Completed NCT01370070 - MK-2206 in Recurrent Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT06228079 - Adjuvant vs Surgery Only in Early-stage Recurrent NPC Phase 3
Terminated NCT04458909 - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Phase 3
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2